Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles

The cytosolic innate immune sensor cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is crucial for priming adaptive antitumour immunity through antigen-presenting cells (APCs). Natural agonists, such as cyclic dinucleotides (CDNs), activate the cGAS-STING pathway, but their clinical translation is impeded by poor cytosolic entry and serum stability, low specificity and rapid tissue clearance. Here we developed an ultrasound (US)-guided cancer immunotherapy platform using nanocomplexes composed of 2 ' 3 '-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) electrostatically bound to biocompatible branched cationic biopolymers that are conjugated onto APC-targeting microbubbles (MBs). The nanocomplex-conjugated MBs engaged with APCs and efficiently delivered cGAMP into the cytosol via sonoporation, resulting in activation of cGAS-STING and downstream proinflammatory pathways that efficiently prime antigen-specific T cells. This bridging of innate and adaptive immunity inhibited tumour growth in both localized and metastatic murine cancer models. Our findings demonstrate that targeted local activation of STING in APCs under spatiotemporal US stimulation results in systemic antitumour immunity and improves the therapeutic efficacy of checkpoint blockade, thus paving the way towards novel image-guided strategies for targeted immunotherapy of cancer. Activation of the STING pathway in antigen-presenting cells has been proposed as a strategy to stimulate the adaptive immune response against tumours, but its clinical application is hampered by the instability, low specificity and low cytosolic entry of natural STING agonists. Here the authors present a platform for targeted ultrasound-mediated cytosolic delivery of STING agonists that shows efficacy in different animal tumour models and improves the response to checkpoint blockade therapies.

Automated summary

Researchers have developed a novel ultrasound-guided cancer immunotherapy platform that activates the immune response and enhances cancer treatment by targeting the STING pathway in APCs. This study provides a new strategy for targeted immunotherapy.